Inflammatory Oesophageal Disorders
Dr. Falk Pharma GmbH is active in eosinophilic esophagitis and in the prevention of oesophageal strictures after endoscopic treatment, with a clear focus on conditions affecting the oesophagus and swallowing function.
- Eosinophilic esophagitis
- Oesophageal stricture prevention
- Budesonide orodispersible tablets
The sponsor also funds work on acute radiation proctitis, extending its interest in gastrointestinal inflammation beyond the upper digestive tract.
Intestinal Autoimmune and Gluten-related Disease
Another major area of interest is celiac disease, particularly persistent symptoms and mucosal injury in patients maintaining a gluten-free diet.
- Celiac disease
- Symptom control
- Mucosal healing
Research in this field includes therapies aimed at reducing ongoing intestinal inflammation and improving disease-related discomfort in adults.
Hepatobiliary Cholestatic Disease
The sponsor shows strong involvement in primary sclerosing cholangitis, including studies addressing disease activity, progression, and treatment tolerability in a chronic cholestatic liver disease.
- Primary sclerosing cholangitis
- Norursodeoxycholic acid
- Norucholic acid
This therapeutic area reflects a sustained interest in bile acid-related approaches for complex hepatobiliary disorders.
Motility and Functional Upper Gastrointestinal Disorders
Dr. Falk Pharma GmbH also funds research in idiopathic and diabetic gastroparesis, focusing on impaired gastric emptying and related symptom burden.
- Gastroparesis
- Upper gastrointestinal motility
- Naronapride
These studies place emphasis on digestive motility disorders that affect meal tolerance, nausea, and postprandial discomfort.
